GCL
SAGE

Glazer Capital LLC’s Sage Therapeutics SAGE Stock Holding History

Glazer Capital LLC’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-441,108
Closed -$4.02M – 334
2025
Q2 		$4.02M Buy
+441,108
New +$3.24M 0.14% 99

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Glazer Capital LLC's SAGE Position: Q3 2025 in Review

Glazer Capital LLC sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 441,108 shares — an estimated $4.02M sold.

Glazer Capital LLC first reported a position in SAGE in Q2 2025 and held it in 1 quarter. The position peaked at $4.02M in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Glazer Capital LLC reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Glazer Capital LLC sold 441,108 Sage Therapeutics shares in Q3 2025, an estimated $4.02M.
  • Glazer Capital LLC first reported a position in Sage Therapeutics in Q2 2025 and held it in 1 quarter.
  • Glazer Capital LLC's Sage Therapeutics position peaked at $4.02M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Glazer Capital LLC's 13F filing for Q3 2025, filed 13 Nov 2025.